Eric Jia-Sobota, Founder, Author at EverGlade Consulting

Eric Jia-Sobota, Founder

Eric Jia-Sobota is the National Leader of EverGlade’s Consulting Practice and the Founder of the Company. Eric’s consulting experience spans almost two decades across a breadth of industries, including, Federal Contracting, Life Sciences, Nonprofit, Technology, Construction, Healthcare, and others. View Eric's resume at https://ericjia-sobota.com/

Eric Jia-Sobota
drug-resistant bacterial infections

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

Leave a Comment / BARDA, EverGlade Insights / By

PBS+AMR+2025+SSN+-+Final The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat […]

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens Read More »

anti-microbial

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials

Leave a Comment / DPA, EverGlade Insights / By

HHS+DPA+T3+RFI_Antimicrobials+-+Clean+copy+11-7-24+(002) The U.S. Department of Health and Human Services (HHS) Defense Production Act (DPA) Title III Program recently issued a Request for Information (RFI) aimed at strengthening the domestic production of anti-microbial products. This initiative seeks input from industry to assess current capacities and capabilities in producing essential anti-microbials critical for public health and national

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials Read More »

antimicrobial-resistant (AMR) pathogens and viruses

NIAID Omnibus Broad Agency Announcement (BAA)

Leave a Comment / EverGlade Insights, NIAID, Time Sensitive / By

Pre-solicitation_Notice_-_BAA2025-1_Final Overview of Solicitation The upcoming 2026 Omnibus Broad Agency Announcement (BAA) is from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS). NIAID’s mission centers on understanding, treating, and preventing infectious, immunologic, and allergic diseases. Through

NIAID Omnibus Broad Agency Announcement (BAA) Read More »

Marburg virus (MARV) and Sudan virus (SUDV) vaccines clinical trials

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines

Leave a Comment / BARDA, EverGlade Insights, Time Sensitive / By

SSN_MARV__SUDV_Vaccines Purpose The Biomedical Advanced Research and Development Authority (BARDA), under the Administration for Strategic Preparedness and Response (ASPR) has issued a Sources Sought Notice (SSN). The subject of this SSN is Marburg virus (MARV) and Sudan virus (SUDV) vaccines in active or completed Phase 2 clinical trials. Insights on current and prospective MARV and

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines Read More »

pathophysiology lymphatic system and diseases

Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE)

Leave a Comment / ARPA-H, EverGlade Insights / By

GLIDE_ISO_ARPA-H-SOL-24-111_Final_29_OCT_2024 Program Overview An estimated 10 million Americans are impacted by primary lymphatic diseases, and lymphatic dysfunction contributes to the pathophysiology of many widespread chronic illnesses. Despite the importance of the lymphatic system in disease, there are currently zero FDA-approved treatments, medical devices, or therapies specifically targeting lymphatic growth and function. To catalyze a future

Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) Read More »

EverGlade Consulting

EverGlade Consulting Continues Growth with Addition of Nathan Clark

Leave a Comment / EverGlade Insights / By

EverGlade Consulting, is pleased to announce the appointment of Nathan Clark as Director, effective November 2024. Mr. Clark brings an extensive background in government contracting and federal funding management, making him a valuable addition to the EverGlade team. Nathan Clark joins EverGlade Consulting with an impressive portfolio, having recently served as the BARDA portfolio leader

EverGlade Consulting Continues Growth with Addition of Nathan Clark Read More »

MTEC RPP military medical needs

Medical Technology Enterprise Consortium (MTEC) Multi-Topic Request for Proposals

Leave a Comment / EverGlade Insights, MTEC / By

MTEC-FY-2025-Multi-Topic-Pre-Announcement Overview of Solicitation The Medical Technology Enterprise Consortium (MTEC) has released an exciting pre-announcement for its 2025 Multi-Topic Request for Proposals (RPP). This RPP calls for innovative medical prototypes addressing a range of focus areas critical to supporting military operations and improving healthcare delivery in challenging environments. Here’s an overview of what to expect

Medical Technology Enterprise Consortium (MTEC) Multi-Topic Request for Proposals Read More »

rapid medical countermeasure (MCM) RPP

MCDC Requests Prototype Projects

Leave a Comment / EverGlade Insights, JPEO / By

MCDC 25-01 Innovative Drug Development Pipeline Methods for Rapid Medical Countermeasure (MCM) Development This solicitation from the Medical CBRN Defense Consortium (MCDC), in support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) represents a Request for Prototype Proposals (RPP). This RPP (MCDC 25-01) calls for innovative drug development pipeline

MCDC Requests Prototype Projects Read More »

curative cell therapies_DECIDE-ET_ARPA-H

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

ARPA-H_DECIDE-ET_Solicitation_DRAFT Overview of Exploration Topic Although Academic Medical Centers (AMCs) have developed many advanced therapies for rare and fatal diseases,  access to AMCs remains limited due to outdated production methods and inadequate quality validation. To enhancing quality assurance technologies at AMCs, the Advanced Research Projects Agency for Health (ARPA-H) has initiated the Decentralized Engineering of

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic Read More »

in silico modeling for ADME-Tox simulation

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

CATALYST_ISO_(DRAFT) Overview of CATALYST Solicitation Current in vivo animal model testing methods often fail to predict human drug safety accurately, leading to inefficiencies and high costs. The Health Science Futures (HSF) Office of the Advanced Research projects Agency for Health (ARPA-H) has introduced the CATALYST program to transform drug development. This program will foster the

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening Read More »

Gene therapy

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding

Leave a Comment / ARPA-H, EverGlade Insights / By

EverGlade Consulting, a national consulting firm, has helped Cirsium Biosciences successfully secure up to $61 million in funding to create a rapid, safe, scalable, and low-cost plant-based manufacturing platform to drastically reduce production time and cost of viral vector-based gene therapies. How Funding Will Be Used The $61 million in ARPA-H funding will enable Cirsium

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding Read More »

nucleic acid-based therapeutics

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis

Leave a Comment / BARDA, EverGlade Insights / By

PrEP_Solicitation_Nucleic_Acid_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of long-acting nucleic acid-based platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The specific goals of these PrEP DEV awards include

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis Read More »

Scroll to Top